A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers
Status:
Completed
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the absolute bioavailability of a single,
fixed subcutaneous (SC) dose of aducanumab compared with a single weight-based intravenous
(IV) dose of aducanumab in healthy volunteers.
The secondary objectives of this study are to assess the safety and tolerability of
aducanumab administered SC in healthy volunteers and to characterize additional
pharmacokinetic (PK) parameters of a single, fixed SC dose of aducanumab and a weight-based
IV dose of aducanumab in healthy volunteers.